AbbVievsEnvista

ABBV and NVST stock compared: price, dividend, valuation and results, from SEC filings.

NVST

Envista Holdings Corporation

$24.14

Value $4.0B

-1.43%
NVST's page

AbbVie (ABBV) has a market value of $527B and Envista (NVST) $4.0B. Over the last year, with dividends, ABBV moved +32.1% and NVST +24.4%. The P/E is 51.2 for ABBV and 6.2 for NVST. Dividend yield: ABBV 2.32%, NVST none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$527B

    NVST$4.0B

    ABBV is 133 times NVST

  • Revenue, 12 months

    ABBV$66.0B

    NVST$2.9B

    ABBV is 23 times NVST

  • Net income, 12 months

    ABBV$10.3B

    NVST$634M

    ABBV is 16 times NVST

  • Operating margin

    ABBV32.2%

    NVST25.4%

    6.8 points apart

  • ROIC

    ABBV25.7%

    NVST14.8%

    10.9 points apart

  • P/E

    ABBV51.2

    NVST6.2

    ABBV is 8.2 times NVST

  • Dividend yield

    ABBV2.3%

    NVST0.0%

    2.3 points apart

  • 5-year return

    ABBV+205.0%

    NVST-43.6%

    248.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+205.0%

NVST-43.6%

10020030020222023202420252026
Returns by period
PeriodABBVWith dividendsNVSTWith dividends
1 year since November 14, 2025+32.1%Price +28.3%+24.4%Price +24.4%
3 years since November 16, 2023+138.4%+33.6% a yearPrice +115.6%+4.5%+1.5% a yearPrice +4.5%
5 years since November 15, 2021+205.0%+25.0% a yearPrice +155.1%-43.6%-10.8% a yearPrice -43.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieNVSTEnvista

Valuation

ABBVNVST
Valuation
Price$298.12$24.14
Market value$527B$4.0B
Enterprise value (EV)$597B$4.2B
P/E51.26.2
P/E, 5-year median57.024.6
P/B–1.3
EV/EBIT28.15.8
Free cash flow yield3.6%6.1%

Results and growth

ABBVNVST
Results and growth
Revenue, 12 months$66.0B$2.9B
Net income, 12 months$10.3B$634M
Free cash flow, 12 months$18.9B$242M
Earnings per share, 12 months$5.81$3.87
Revenue growth, year on year8.6%8.3%
Revenue growth a year, past+5.9%over 5 years+7.1%over 5 years
EPS growth a year, past-2.8%over 5 years+7.0%over 5 years

Margins and returns on capital

ABBVNVST
Margins and returns on capital
Gross margin73.7%55.9%
Operating margin32.2%25.4%
Net margin15.7%22.0%
ROIC25.7%14.8%
ROE–20.5%

Balance sheet

ABBVNVST
Balance sheet
Cash$10.8B$1.2B
Total debt$80.9B$1.6B
Net debt / EBITDA3.20.3
Interest cover7.1×–

Dividends and buybacks

ABBVNVST
Dividends and buybacks
Dividend yield2.3%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%4.2%
Shareholder yield2.5%4.2%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or NVST

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Envista?

By market value, AbbVie ($527B) is about 133.2 times Envista ($4.0B), at today's prices.

How did ABBV and NVST stock do over the last 5 years?

Since November 15, 2021, ABBV's price moved +155.1% and NVST's -43.6%. With dividends: ABBV +205.0% (+25.0% a year), NVST -43.6% (-10.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or NVST?

The dividend yield at today's price is 2.32% for AbbVie and none for Envista. Over the last twelve months they paid $6.92 and – per share.

What is the P/E of ABBV and NVST?

At today's price, the P/E is 51.2 for ABBV and 6.2 for NVST. The median of the last five years was 57.0 and 24.6, which shows where each stands against its own past.

Which has the higher profit margins, AbbVie or Envista?

Over the last twelve months, the net margin was 15.7% for AbbVie and 22.0% for Envista, and the operating margin 32.2% and 25.4%. Revenue was $66.0B and $2.9B.

Which is the better investment, AbbVie or Envista?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.